1
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:October 19, 2020Available
ICCA: 14 Clinical Trials, Page 1 of 2
Hide Studies Not Open or Pending
2
Liver Transplantation for Early Intrahepatic Cholangiocarcinoma
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:August 19, 2020Recruiting
3
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Condition(s):Intrahepatic Cholangiocarcinoma; Mixed Hepatocellular Cholangiocarcinoma; CholangiocarcinomaLast Updated:June 8, 2017Completed
4
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Condition(s):Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver MetastasesLast Updated:March 19, 2020Recruiting
5
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Condition(s):Solid TumorLast Updated:October 31, 2019Completed
6
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Condition(s):Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and CholangiocarcinomaLast Updated:February 1, 2021Recruiting
7
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:July 23, 2020Not yet recruiting
8
Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma (CCA) Harboring FGFR2 Gene Rearrangements
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene RearrangementsLast Updated:February 7, 2020Not yet recruiting
9
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
Condition(s):Cholangiocarcinoma, IntrahepaticLast Updated:August 19, 2020Enrolling by invitation
10
Futibatinib in Patients With Specific FGFR Aberrations
Condition(s):Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)Last Updated:November 10, 2020Recruiting